Author: Vere Hodge, R Anthony
Title: Meeting report: 30th International Conference on Antiviral Research, in Atlanta, GA, USA Document date: 2018_6_28
ID: tudwns0r_18
Snippet: Amdoxovir (DAPD, (À)-b-D-2,6-diaminopurinedioxolane) had activity against both HIV and HBV. DAPD is converted by adenosine deaminase to the corresponding guanosine anaologue, DXG. At that time (late 1990s), AZT-and 3TC-resistant strains of HIV were limiting the effectiveness of therapy. In cell culture assays using resistant clinical strains, DXG retained good activity, there being only a 2.3-fold decrease with the double AZT/3TC-resistant mutat.....
Document: Amdoxovir (DAPD, (À)-b-D-2,6-diaminopurinedioxolane) had activity against both HIV and HBV. DAPD is converted by adenosine deaminase to the corresponding guanosine anaologue, DXG. At that time (late 1990s), AZT-and 3TC-resistant strains of HIV were limiting the effectiveness of therapy. In cell culture assays using resistant clinical strains, DXG retained good activity, there being only a 2.3-fold decrease with the double AZT/3TC-resistant mutations (67N/70R/184V/215Y/219E). DAPD was progressed to Phase IIa trials in HIV patients. DAPD (500 mg twice daily for two weeks) gave modest activity as monotherapy but, when added to current therapy, there was about 2 log 10 reduction in plasma HIV-1 RNA levels.
Search related documents:
Co phrase search for related documents- cell culture and current therapy: 1, 2, 3
- cell culture and good activity: 1, 2, 3, 4, 5, 6, 7, 8, 9
- cell culture and modest activity: 1, 2, 3
- clinical strain and IIa trial: 1
- current therapy and HIV patient: 1
- good activity and IIa trial: 1
- good activity and modest activity: 1, 2
Co phrase search for related documents, hyperlinks ordered by date